Dr. Mike Goodnough
Dr. Goodnough has accumulated a great deal of toxin expertise over the past 33 years specializing in the research and development of improving the toxin's characteristics and discovering new applications. Mike has been a repeat speaker at the Interagency Botulinial Research Committee Conference as well as being a subject matter expert to the U. S. Food and Drug Administration. He also is a co-author on seven issued patents. Mike obtained his B.S. in Bacteriology and Genetics, a M.S. in Microbiology, and a Ph.D. in Microbiology from the University of Wisconsin-Madison. Mike wrote his doctoral thesis on the medical use of botulinum toxin.
DR. aaron Chamberlain
Dr. Chamberlain has 29 years of Research and Pre-Clinical Development experience in academics, pharma and biotech companies. Prior to Object, Aaron worked as Research Fellow for Takeda Pharmaceuticals, the largest pharmaceutical company in Japan, at their San Diego research site, serving as the research representative on clinical development teams, as a project leader for various research programs, and on due diligence efforts for acquisitions and collaborations. His group brought programs from the concept stage into the clinic. He also developed pre-clinical drugs in scientific positions at the Lilly Biotechnology Center and Xencor Inc. He maintains active academic connections, lecturing regularly at the University of California, San Diego, and has a strong interest in bridging academic and industrial science. He has co-authored over 23 scientific papers and more than a dozen patent applications. Aaron was a Postdoctoral Research Fellow at the University of Oxford (Molecular Sciences Centre) and UCLA (Biochemistry Dept) and received his PhD from Berkeley’s Department of Molecular and Cellular Biology.